AZK is likely to break W200 billion in annual sales

Boosted by increase in sales of Crestor (rosuvastatin) and Atacand as strategic items, AstraZeneca Korea saw its sales in 2007 exceed 200 billion won, up 16 percent from last year's 172.7 billion won. The combined sales of Crestor and Atacand are estimated to reach 100 billion won.

We have seen great upturns for our annual sales thanks to an increase in the two medicines,'' a ranking compan...